Inventor

KOWALEWSKI DANIEL JOHANNES

DE154 patents

Patents

50 patents

US10772915B2Sep 15, 2020

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH5 citations93

US10709738B2Jul 14, 2020

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH3 citations93

US10695374B2Jun 30, 2020

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH5 citations93

US10286052B2May 14, 2019

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

IMMATICS BIOTECHNOLOGIES GMBH25 citations93

US11732021B2Aug 22, 2023

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH3 citations84

US11655281B2May 23, 2023

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH3 citations84

US11117941B2Sep 14, 2021

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH3 citations84

US11020433B2Jun 1, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH2 citations84

US10899811B2Jan 26, 2021

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH5 citations84

US10899810B2Jan 26, 2021

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH6 citations84

US10167317B1Jan 1, 2019

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

IMMATICS BIOTECHNOLOGIES GMBH6 citations84

US10144763B2Dec 4, 2018

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

IMMATICS BIOTECHNOLOGIES GMBH5 citations84

US10377797B2Aug 13, 2019

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

IMMATICS BIOTECHNOLOGIES GMBH13 citations83

US12162917B2Dec 10, 2024

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US12076379B2Sep 3, 2024

A*03 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US12065471B2Aug 20, 2024

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11951132B2Apr 9, 2024

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11945850B2Apr 2, 2024

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11918607B2Mar 5, 2024

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11872270B2Jan 16, 2024

A*03 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11833193B2Dec 5, 2023

A*03 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11801264B2Oct 31, 2023

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11779606B2Oct 10, 2023

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11680089B2Jun 20, 2023

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11667685B2Jun 6, 2023

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11655280B2May 23, 2023

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH2 citations73

US11629177B2Apr 18, 2023

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11603397B2Mar 14, 2023

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH2 citations73

US11376281B2Jul 5, 2022

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11369636B2Jun 28, 2022

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11357797B2Jun 14, 2022

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11214604B2Jan 4, 2022

Peptides for use in immunotherapy against cancers

IMMATICS BIOTECHNOLOGIES GMBH1 citations73

US11208449B2Dec 28, 2021

Peptides for use in immunotherapy against cancers

IMMATICS BIOTECHNOLOGIES GMBH3 citations73

US11208448B2Dec 28, 2021

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11197892B2Dec 14, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11179418B2Nov 23, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11154576B2Oct 26, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11147839B2Oct 19, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11147838B2Oct 19, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11141437B2Oct 12, 2021

Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11111281B2Sep 7, 2021

B*44 restricted peptides for use in immunotherapy against cancers and related methods

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11103535B2Aug 31, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11077142B2Aug 3, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11065279B2Jul 20, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11058727B2Jul 13, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11052114B2Jul 6, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11052113B2Jul 6, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11040069B2Jun 22, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11033585B2Jun 15, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

US11033583B2Jun 15, 2021

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

IMMATICS BIOTECHNOLOGIES GMBH0 citations73

Showing the top 50 of 154 patents by PatentIndex Score.